Propped up by hectic domestic road construction activity, Cummins India's industrial business grew by an astonishing 34.6% in H1 - with revenue growth in excess of 20% for last three quarters - with notable advances in compressors (35% growth), construction (50%) and railways (50%). After reversing course last fiscal, the distribution business - reinforced by railways, construction and mining segments - ascended by some 12% in the first half of current fiscal. Despite some pick up in off take for nearly all sorts of gensets from realty space, domestic power generation business...
IWL, one of the largest integrated wind power solution providers in India, manufactures wind turbine generators and provides ovides complete turnkey solutions such as supply of WTG, land acquisition, infrastructure development, power...
If recent trend in sales of LG Balakrishnan is anything to go by, then the domestic two wheeler industry is showing discernible signs of revival. Income from operations (standalone) jumped 10.1% to Rs 309.95 crs ($46.5m) in Q2 - the best reading in last nine quarters - not least due to hefty rise in bellwether transmission business sales (10.2%), catapulting its revenue share to 79.1%. Slackness in two wheeler industry in last few years could do little to prevent massive rise in transmission business revenue (standalone) share - 78.8% in FY16 from 67.3% in FY13....
in volumes and value respectively. On the other hand, light hair oil exhibited a growth of 0.2% and 1.2% in volumes and value respectively, over the same time period, with Almond Drops hair oil displaying a de growth of 1.5% and...
Growing at an expeditious pace in the first quarter of this fiscal, the two wheeler market seems to have rejuvenated from the dull volume growth in the last fiscal. Hefty scooter sales (growth of 27.1%) and motorcycles sales (growth of 8.9%), which has been a laggard in recent years, backed the 14.3% growth in the two wheeler segment. Such healthy dispatches in the two wheeler industry particularly scooters of Honda proved opportune to Fiem. The company posted a strong growth of 20.5% in its income from operations in Q1FY17 of Rs 245.18 crs ($36.7m)...
Slowdown in sales growth (6%) last quarter left investors uncertain about the pickup in demand from overseas markets, particularly US. Not only sales growth slid to lowest in last few quarters, but operating margins were also lower - 19.8% Vs 20.7% in the same quarter a year ago, resulting in cut in our estimates- 4.1% for FY17. Steady rise in cotton prices in last few months explains the shrinkage in material margins 46.5% Vs 50.1% in Q1FY16 and 47.4% in Q4FY16. Despite the growing revenue share of home textiles division and increasing value added products (read: institutional bedding, fashion bedding and utility...
To keep pace with the competition around, GICHFL managed to start off well in the year with a loan book growth of 19.2% achieved in Q1FY17 yo-y. The book size of ~Rs 8210 crs ($1234.0m) is strengthened by the high yielding LAP (loan against property) portfolio which brings additional 200-250 bps yield than the home loans. Despite continuous foreclosures, the company is able to sustain the growth in the portfolio. The disbursement in the last quarter leaped 15.3% to Rs 626 crs ($94.1m) as against Rs 543 crs ($81.6m) in Q1FY16, and...
After two dull quarters when sales grew by just over 7%- sales rejuvenated in Q1 - grew by 15.5% to Rs 335.13 crs ($50.2m) compared to Rs 290.07 crs ($43.m) in the same quarter a year ago. Stoked by lower raw material and fuel & power costs, OPMs expanded by some 600 bps to 15.8%...
To augment its business, Essel Propack counts on the unceasing share of non oral care category of its revenue which is targeted to even the share of oral care in a couple of years. It managed to add spin to its AMESA business last quarter, improving its non oral care share to 50.3% shouldered by strong recovery in cosmetic and pharma category in the Indian market. To bolster its overseas presence, Essel continues to eye on Europe segment which has a huge scope of capacity expansion (acquired 100% stake in Essel Deutschland Germany recently). Q1FY17 didn't turn out well for Europe ...
JBCPL, one of India's leading pharmaceutical companies, manufactures and markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with a strong presence in in Russia, Ukraine, CIS countries and South Africa.
The income from operations in FY16, which was the highest in a decade, registered a growth of a 9.7% y-o-y. The company which has seen better profit margins in the past (read: FY10 and FY11), exhibited an operating profit margin of 16.4% and a net profit margin of 12.2 During the year, Biotech Laboratories (Pty.) Ltd., South Afri subsidiary of the company, with company’s interest going up to 95.24% from 49%. This strategic investment will allow the Company to expand its business in South Africa and SADC countries, which hold good growth potential.The domestic formulation business which somehow managed to contribute 35% in the Q4FY16, grew almost 31% q-o-q, contributing a beefy 43% last quarter i.e., Q1FY17. The volatile currency situation cast down the exports, which rendered a decline of 11.2% q-o-q.
